HEAL Initiative: Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) (UG3/UH3 Clinical Trial Required)
The summary for the HEAL Initiative: Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) (UG3/UH3 Clinical Trial Required) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
HEAL Initiative: Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) (UG3/UH3 Clinical Trial Required): This FOA is intended to solicit two-phase research applications to develop, adapt and test interventions and strategies to prevent initiation of opioid misuse and development of OUD in at-risk older adolescents and young adults (ages 16-30). The goal is to stimulate research studies conducted in populations and geographic areas most affected by the opioid crisis or with indicators of an emerging crisis. Of priority are studies that target older adolescents and young adults in health care settings (including primary care, surgical, orthopedic and other specialty care, dental care, emergency departments, urgent care, HIV/STI and reproductive health clinics, prenatal clinics, school-based health centers, federally qualified health centers, military medicine settings, occupational health settings), justice settings (including criminal justice, juvenile justice, as well as child welfare and other systems that cross with the justice system) and other systems and settings. Studies that include understudied at-risk older adolescent and young adult populations are strongly encouraged. Examples include, but are not limited to individuals in rural or reservation settings, women, veterans, and individuals with a history of polysubstance use or mental disorders.
Federal Grant Title: | HEAL Initiative: Preventing Opioid Use Disorder in Older Adolescents and Young Adults (ages 1630) (UG3/UH3 Clinical Trial Required) |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education Health Income Security and Social Services |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | RFA-DA-19-035 |
Type of Funding: | Cooperative Agreement |
CFDA Numbers: | 93.213, 93.242, 93.273, 93.279, 93.865 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | March 13th, 2019 |
Original Application Deadline: | March 13th, 2019 |
Posted Date: | December 10th, 2018 |
Creation Date: | December 10th, 2018 |
Archive Date: | April 18th, 2019 |
Total Program Funding: | $10,000,000 |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | December 10th, 2018 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-19-035.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required)
- • Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data...
- • Leveraging Data at Scale to Understand Natural Product Impacts on Whole Person Health (R01...
- • Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clin...
- • Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials o...
- • Probiotics for Pediatric Illnesses
- • Cam Practitioner Research Education Project Grant Partnership
- • Complementary and Alternative Medicine Career Transition Award (K22)
- More Grants from the National Institutes of Health
- • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
- • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
- • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
- • AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
- • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)